Home   |   About Us   |   Research & Development   |   Clinical Trials   |   News   |   Contact Us 

Research & Development

Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.

Diabetic Neuropathy

Neuropathy associated with diabetes arises from complex metabolic and neurotrophic imbalances, and can affect single or multiple nerves and both motor as well as sensory function. Symptoms can include pain or a loss of sensation in the extremities, muscle weakness, loss of bowel or bladder control, digestive problems, and reduced sexual potency. A recent survey found that 65% of diabetic patients have mild or severe forms of neuropathy, and that in a two year period neuropathy led to more than 500,000 hospitalizations for diabetic patients. The mainstay of treatment for diabetic neuropathy is improved glucose control, which can be helpful in “acute” stages but is usually ineffective in chronic disease. Palliative treatment includes the use of pain relievers and anti-seizure drugs in attempt to relieve pain and “burning” feet.

In preclinical studies, long-term administration of GLY-230 to diabetic rats improved measures of metabolic imbalance and oxidative stress in peripheral nerves.

Glycadia Pharmaceuticals          1880 JFK Blvd, Suite 200          Philadelphia, PA 19103
Tel 215.557.8021     ·     Fax 215.557.8053

Developing safe and effective treatments for diabetic complications.™